ERBB2 and gastric cancer: Even if we believe that also HER-2 positive GC requires a classification, we decided to exclude these patients from our study considering the different biology of this disease, the potential prognostic role of HER-2 expression and the possible confounding factor represented by trastuzumab treatment.